← Back to headlines
Experimental Lung Cancer Drug Ivonescimab Shows Promise, Reduces Death Risk by 34%
A highly anticipated study revealed that the experimental lung-cancer drug ivonescimab reduced the risk of death by 34% compared with another drug, though investors' reaction was muted.
1 Jun, 12:06 — 1 Jun, 12:06
